The only single-pill regimen  POWERED BY DOLUTEGRAVIR AT THE CORE

triumeq bottle
Not actual size

TRIUMEQ

  • Superior efficacy in treatment-naive patients vs Atripla, darunavir/r and atazanavir (in women)*1-3
  • High barrier to resistance2,4-7
  • Booster-free dosing6

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

 

Indication and Dosing

Once-Daily TRIUMEQ Makes Dosing and Administration Simple for Your Patients*†‡§

 

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

 

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

 

*In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/ 3TC 300 mg were used. Bioequivalence has been demonstrated.

TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required.

TRIUMEQ is not recommended for patients with integrase inhibitor resistance.

§TRIUMEQ is not recommended for co-administration with efavirenz, nevirapine, rifampicin, or tipranavir/ritonavir

Dosing recommendations for TRIUMEQ (patients aged ≥12 and weighing ≥40 kg)8*†‡

Patients without documented or clinically suspected resistance to the integrase class

One tablet,
Once Daily

Convenient dosing regimen8

  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs One pill, once daily
  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs No time-of-day restrictions
  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs No food restrictions
  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs No boosting required
  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs Few clinically
    significant DDIs
  • Convenient dosing: one pill, QD; No time or food restrictions; no boosting/additional renal monitoring; few significant DDIs No additional renal monitoring required

For further information, please see the Summary of Product Characteristics - SPC

Drug-Drug Interactions

TRIUMEQ has few clinically significant drug-drug interactions8,9 

HIV-1 Antiviral Agents

NNRTI

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Etravirine without boosted protease inhibitors / Dolutegravir

Protease Inhibitors/
Dolutegravir

Dolutegravir ↓

AUC ↓ 71 %

Cmax ↓ 52 %

Cτ ↓ 88 %

Etravirine

(induction of UGT1A1 and CYP3A enzymes)

Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration.

Since the recommended dose of dolutegravir is 50 mg twice daily for patients taking etravirine without boosted protease inhibitors, Triumeq is not recommended for patients taking etravirine without co-administration of atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir (see further below in table).

Lopinavir + Ritonavir +
Etravirine/
Dolutegravir

Dolutegravir

AUC ↑ 11 %

Cmax ↑ 7 %

Cτ ↑ 28 %

Lopinavir

Ritonavir

Etravirin

No dose adjustment is necessary.

Darunavir + Ritonavir +
Etravirine/
Dolutegravir

Dolutegravir ↓

AUC ↓ 25 %

Cmax ↓ 12 %

Cτ ↓ 36 %

Darunavir

Ritonavir

Etravirine

No dose adjustment is necessary.

Efavirenz/Dolutegravir

Dolutegravir ↓

AUC ↓ 57 %

Cmax ↓ 39 %

Cτ ↓ 75 %

Efavirenz (historical controls)

(induction of UGT1A1 and CYP3A enzymes)

Since the dose of dolutegravir is 50 mg twice daily when co-administered with efavirenz, the co-administration of efavirenz with Triumeq is not recommended.

Nevirapine/Dolutegravir

Dolutegravir ↓

(Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction)

Co-administration with nevirapine may decrease dolutegravir plasma concentration due to enzyme induction and has not been studied.

Effect of nevirapine on dolutegravir exposure is likely similar to or less than that of efavirenz.

Since the dose of dolutegravir is 50 mg twice daily when co-administered with nevirapine, the co-administration of nevirapine with Triumeq is not recommended.

Rilpivirine

Dolutegravir

AUC ↑ 12 %

Cmax ↑ 13 %

Cτ ↑ 22 %

Rilpivirine

No dose adjustment is necessary.

HIV-1 Antiviral Agents

NRTI

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Tenofovir






Emtricitabine, didanosine,
stavudine, zidovudine.

Dolutegravir

AUC ↑ 1 %

Cmax ↓ 3 %

Cτ ↓ 8 %

Tenofovir


Interaction not studied

No dose adjustment is necessary when Triumeq is combined with nucleoside reverse transcript inhibitors.




Triumeq is not recommended for use in combination with emtricitabine containing products, since both lamivudine (in Triumeq) and emtricitabine are cytidine analogues (i.e. risk for intracellular interactions).

HIV-1 Antiviral Agents

Protease Inhibitors

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Atazanavir/Dolutegravir

Dolutegravir ↑

AUC ↑ 91 %

Cmax ↑ 50 %

Cτ ↑ 180 %

Atazanavir (historical controls)

(inhibition of UGT1A1 and CYP3A enzymes)

No dose adjustment is necessary.

Atazanavir + Ritonavir/
Dolutegravir

Dolutegravir ↑

AUC ↑ 62 %

Cmax ↑ 34 %

Cτ ↑ 121 %

Atazanavir

Ritonavir

No dose adjustment is necessary.

Tipranavir + Ritonavir/
Dolutegravir

Dolutegravir ↓

AUC ↓ 59 %

Cmax ↓ 47 %

Cτ ↓ 76 %

Tipranavir

Ritonavir

(induction of UGT1A1 and CYP3A enzymes)

Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with tipranavir/ritonavir, the co-administration of tipranavir/ritonavir with Triumeq is not recommended.

Fosamprenavir + Ritonavir/
Dolutegravir

Dolutegravir ↓

AUC ↓ 35 %

Cmax ↓ 24 %

Cτ ↓ 49 %

Fosamprenavir

Ritonavir

(induction of UGT1A1 and CYP3A enzymes)

Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies.

No dose adjustment is necessary.

Nelfinavir/Dolutegravir

Dolutegravir

(Not studied)

No dose adjustment is necessary.

Lopinavir + Ritonavir/
Dolutegravir

Dolutegravir

AUC ↓ 4 %

Cmax 0 %

C24 ↓ 6 %

Lopinavir

Ritonavir

No dose adjustment is necessary.

Darunavir + Ritonavir/
Dolutegravir

Dolutegravir ↓

AUC ↓ 22 %

Cmax ↓ 11 %

Cτ ↓ 38 %

Darunavir

Ritonavir

(induction of UGT1A1 and CYP3A enzymes)

No dose adjustment is necessary.

Other Antiviral Agents

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Telaprevir / Dolutegravir + Abacavir + Lamivudine

Dolutegravir ↑

AUC ↑ 25 %

Cmax ↑ 19 %

Cτ ↑ 37 %

Telaprevir (historical controls)

(inhibition of CYP3A enzyme)

Interaction with abacavir not studied

Interaction with lamivudine not studied

No dose adjustment is necessary with dolutegravir.

Based on metabolism and clearance of abacavir a clinically significant interaction is unlikely.

Based on metabolism and clearance of lamivudine a clinically significant interaction is unlikely.

Boceprevir / Dolutegravir + Abacavir + Lamivudine

Dolutegravir

AUC ↑ 7 %

Cmax ↑ 5 %

Cτ ↑ 8 %

Boceprevir (historical controls)

Interaction with abacavir not studied

Interaction with lamivudine not studied

No dose adjustment is necessary with dolutegravir.

Based on metabolism and clearance of abacavir a clinically significant interaction is unlikely.

Based on metabolism and clearance of lamivudine a clinically significant interaction is unlikely.

Daclatasvir / Dolutegravir + Abacavir + Lamivudine

Dolutegravir

AUC ↑ 33 %

Cmax ↑ 29 %

Cτ ↑ 45 %

Daclatasvir

Interaction with abacavir not studied

Interaction with lamivudine not studied

Daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent.

Dolutegravir did not change daclatasvir plasma concentration. No dose adjustment is necessary. No clinically significant interaction expected.

Based on abacavir and lamivudine metabolism and clearance a clinically significant interaction is unlikely.

Please see the Liverpool Drug-Drug Interaction Table for further information.

Elbasvir / Grazoprevir / Dolutegravir + Abacavir + Lamivudine

AUC ↑ 16%

Cmax  ↑ 22%

Ctrough 14%

Interaction with abacavir not studied

Interaction with lamivudine not studied

Coadministration of multiple doses of elbasvir / grazoprevir and dolutegravir had no clinically significant effect on the pharmacokinetics of grazoprevir, elbasvir or dolutegravir. No dose adjustments are required. (In 12 subjects). No clinically significant interaction expected.

Based on abacavir and lamivudine metabolism and clearance a clinically significant interaction is unlikely.

Ombitasvir / Paritaprevir/r + Dasabuvir / Dolutegravir + Abacavir + Lamivudine

Dolutegravir ↑ 22-38%

Abacavir exposures were up to 13% lower

Lamivudine Cmax ≤ ↓ 13%

Lamivudine AUC ≤ ↓ 13%

Lamivudine Ctrough ↑ 29%

Coadministration of ombitasvir / paritaprevir/r + dasabuvir and abacavir + lamivudine had no clinically significant effect on the pharamcokinetics of ombitasvir, paritaprevir/r, dasabuvir, dolutegravir, abacavir orlamivudine. No dose adjustment is required. (In 12 HIV/HCV-negative subjects).

Please see the Liverpool Drug-Drug Interaction Table for further information.

Ribavirin / Dolutegravir + Abacavir + Lamivudine

Coadministration has not been studied with dolutegravir

Potential interaction with abacavir

Potential interaction with lamuvudine

Based on metabolism and clearance of dolutegravir a clinically significant interaction is unlikely.

Caution should be exercised when abacavir and ribavirin are coadministered.

No pharmacokinetic interaction observed with lamivudine.

Please see the Liverpool Drug-Drug Interaction Table for further information.

Simeprevir / Dolutegravir + Abacavir + Lamivudine

Coadministration has not been studied with dolutegravir

Interaction with abacavir not studied

Interaction with lamivudine not studied

Based on metabolism and clearance a clinically significant interaction is unlikely.

Coadministration has not been studied with abacavir, but no clinically relevant drug-drug interaction is expected. No dose adjustment is required.

Coadministration has not been studied with lamivudine, but no clinically relevant drud-drug interaction is expected. No dose adjustment is required.

Please see the Liverpool Drug-Drug Interaction Table for further information.

Sofosbuvir / Dolutegravir + Abacavir + Lamivudine

Coadministration has not been studied with dolutegravir

Interaction with abacavir not studied

Interaction with lamivudine not studied

Based on metabolism and clearance of abacavir, there is little potential for interaction.

Based on metabolism and clearance of lamivudine, a clinically significant interaction is unlikely.

Please see the Liverpool Drug-Drug Interaction Table for further information.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Trimethoprim/Sulfamethoxazole

(Co-trimoxazol)/
Abacavir

Trimethoprim/Sulfamethoxazole

(Co-trimoxazol)/
Lamivudine

(160 mg/800 mg once daily for 5 days/300 mg dose)

Interaction not studied

Lamivudine:

AUC ↑ 43 %

Cmax ↑ 7 %

Trimethoprim:

AUC

Sulfamethoxazole:

AUC

(organic cation transporter inhibition)

No Triumeq dosage adjustment necessary, unless patient has renal impairment.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Rifampicin/Dolutegravir

Dolutegravir ↓

AUC ↓ 54 %

Cmax ↓ 43 %

Cτ ↓ 72 %

(induction of UGT1A1 and CYP3A enzymes)

Since the dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, the co-administration of rifampicin with Triumeq is not recommended.

Rifabutin

Dolutegravir

AUC ↓ 5 %

Cmax ↑ 16 %

Cτ ↓ 30 %

(induction of UGT1A1 and CYP3A enzymes)

No dose adjustment is necessary.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Carbamazepine/Dolutegravir

Dolutegravir ↓

AUC ↓ 49 %

Cmax ↓ 33 %

Cτ ↓ 73 %

Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine, DTG/ABC/3TC FDC is not recommended for patients taking carbamazepine.

Phenobarbital/Dolutegravir

Phenytoin/Dolutegravir

Oxcarbazepine/Dolutegravir

Dolutegravir ↓

(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)

Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with these metabolic inducers, DTG/ABC/3TC FDC is not recommended for patients taking these metabolic inducers.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Ranitidine

Interaction not studied.

Clinically significant interaction unlikely.

No dosage adjustment necessary.

Cimetidine

Interaction not studied.

Clinically significant interaction unlikely.

No dosage adjustment necessary.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Cladribine/Lamivudine

Interaction not studied.

In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting.

Some clinical findings also support a possible interaction between lamivudine and cladribine

Concomitant use of Triumeq with cladribine is not recommended.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Methadone/Abacavir

(40 to 90mg once daily for 14 days/600mg single dose, then 600mg twice daily for 14 days)

Abacavir:

AUC

Cmax ↓ 35 %

Methadone:

CL/F ↑ 22 %

Methadone dosage adjustment likely not needed in majority of patients; occasionally methadone re-titration may be required.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Retinoid compounds

(e.g. Isotretinoin)

Interaction not studied

Possible interaction given common pathway of elimination via alcohol dehydrogenase (abacavir-component).

Insufficient data to recommend dosage adjustment.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Ethanol/Dolutegravir

Ethanol/Lamivudine

Ethanol/Abacavir

(0,7 g/kg single dose/
600 mg single dose)

Interaction not studied (Inhibition of alcohol dehydrogenase)

Abacavir:

AUC ↑ 41 %

Ethanol:

AUC

No dosage adjustment necessary.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Dofetilide/Dolutegravir

Dofetilide ↑

(Not studied, potential increase via inhibition of OCT2 transporter)

Triumeq and dofetilide co-administration is contraindicated due to potential life-threatening toxicity caused by high dofetilide concentration.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Magnesium/
aluminium-containing antacids/
Dolutegravir

Dolutegravir ↓

AUC ↓ 74 %

Cmax ↓ 72 %

(Complex binding to polyvalent ions)

Magnesium/ aluminium-containing antacids should be taken well separated in time from the administration of Triumeq (minimum 2 hours after or 6 hours before).

Calcium supplements/
Dolutegravir

Dolutegravir ↓

AUC ↓ 39 %

Cmax ↓ 37 %

C24 ↓ 39 %

(Complex binding to polyvalent ions)

Calcium supplements, iron supplements or multivitamins should be taken well separated in time from the administration of Triumeq (minimum 2 hours after or 6 hours before).

Iron supplements/
Dolutegravir

Dolutegravir ↓

AUC ↓ 54 %

Cmax ↓ 57 %

C24 ↓ 56 %

(Complex binding to polyvalent ions)

Multivitamins/
Dolutegravir

Dolutegravir ↓

AUC ↓ 33 %

Cmax ↓ 35 %

C24 ↓ 32 %

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Prednisone

Dolutegravir

AUC ↑ 11 %

Cmax ↑ 6 %

Cτ ↑ 17 %

No dose adjustment is necessary.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Metformin/Dolutegravir

Metformin ↑

Dolutegravir

When co-administered with dolutegravir 50mg QD: Metformin

AUC ↑ 79 %

Cmax ↑ 66 %

When co-administered with dolutegravir 50mg BID: Metformin

AUC ↑ 145 %

Cmax ↑ 111 %

A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control.

In patients with moderate renal impairment a dose adjustment of metformin should be considered when coadministered with dolutegravir, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

St. John's wort/
Dolutegravir

Dolutegravir ↓

(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected)

Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with St. John's wort, DTG/ABC/3TC FDC is not recommended.

Medical Products by therapeutic areas

Interaction

Geometric mean change (%)

Recommendations concerning co-administration

Ethinyl estradiol (EE) and Norgestromin (NGMN)/
Dolutegravir

Effect of Dolutegravir:

EE

AUC ↑ 3 %

Cmax ↓ 1 %

Effect of Dolutegravir:

NGMN

AUC ↓ 2 %

Cmax ↓ 11 %

Dolutegravir had no Pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone.

No dose adjustment of oral contraceptives is necessary when co-administered with Triumeq.

For a more comprehensive list of interactions, please see the Liverpool Drug-Drug Interaction Tables.

 

For further information, please see the Summary of Product Characteristics - SPC

Safety and Tolerability

In Single dolutegravir showed superiority vs. Atripla® at Weeks 48, 96 and 144 in treatment-naïve adults (TRIUMEQ* QD vs Atripla® QD (N=833))3,4,9

More details on SINGLE

 

TRIUMEQ* Was Generally Better Tolerated vs. Atripla® up to 144 Weeks With Fewer Discontinuations4

 

SINGLE—Most common treatment-related adverse events ≥5% in either arm up to 144 weeks (N=833)4

 

 

 

In ARIA Triumeq showed Superiority vs atazanvir/r at Week 48 in treatment-naïve women (TRIUMEQ QD vs atazanavir/r + TDF/FTC QD (N=495))

 

TRIUMEQ*: Demonstrated favourable tolerability vs ATV/r + TDF/FTC (in Women)2

 

 

  

ARIA- Most common drug-related adverse events (all grades ≥ 5% in either regimen)2

 

 

 

 

 

*In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used. Bioequivalence has been demonstrated.8

 

In the UK, Atripla® is not licensed for initial use in treatment-naïve patients.

 

Atripla® is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.

 

For further information, please see the Summary of Product Characteristics - SPC

HLA-B*5701 Screening

 

Screening for the HLA-B*5701 allele should be performed before prescribing TRIUMEQ8 

Prospective HLA-B*5701 screening: No immunologically confirmed HSR and significant reduction of clinically suspected HSR in the PREDICT-1 study10 

 

PREDICT-1 (CNA106030): pivotal, double blinded, randomised clinical trial to establish the effectiveness of the HLA-B*5701 allele as a predictive marker for abacavir (ABC) hypersensitivity reaction (HSR)1 (ABC) hypersensitivity reaction (HSR)10

1,956 ABC naive subjects randomised 1:1 in a double blinded fashion to:
Arm A) Retrospective HLA B*5701 testing after starting ABC therapy (Controls) Arm B) Prospective HLA-B*5701 screening; positive patients excluded pre- ABC therapy10

HLA-B*5701 screening significantly reduces the risk of an ABC hypersensitivity reaction10

 

Clinical description of ABC HSRs8

  • Almost all patients developing ABC HSRs will have fever and/or rash
  • Other key symptoms include gastrointestinal, respiratory or constitutional symptoms, such as lethargy and malaise

 

If suspected8:

  • TRIUMEQ must be stopped without delay, even in the absence of the HLA-B*5701 allele
  • After stopping treatment with TRIUMEQ for a suspected HSR, TRIUMEQ or any other medicinal product containing ABC or DTG, must never be re-initiated

 

Guidelines recommended11,12

  • EACS and DHHS guidelines recommend screening for HLA-B*5701 before starting ABC-containing antiretroviral therapy, if not previously tested

 

 

For further information around the risk associated with abacavir HSR, please see Abacavir HSR Support.

 

For further information, please see the Summary of Product Characteristics - SPC.

References

  1. Clotet B, Feinberg J, van Lunzen J, et al; on behalf of the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222-2231.
  2. Orrell C, Hagins D, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Published online July 17, 2017. Lancet HIV, doi: 10.1016/S2352-3018(17)30095-4.
  3. Walmsley S, Antela A, Clumeck N, et al; for the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
  4. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515-519.
  5. Molina J-M, Clotet B, van Lunzen J, et al; on behalf of the FLAMINGO Study Team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127-e136. 
  6. TIVICAY Summary of Product Characteristics, July 2017.
  7. Raffi F, Jaeger H, Quiros-Roldan E, et al; on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935. 
  8. TRIUMEQ Summary of Product Characteristics, January 2017.
  9. Zong, J, Borland J, Jerva F, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Int AIDS Soc. 2014;17(Suppl 3):19584.
  10. Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
  11. European AIDS Clinical Society. Guidelines. Version 9.0. October 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed December 1, 2017. 
  12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 28, 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed December 1, 2017.

UK/DTGP/0022/16(1) |December 2017